2-chloro-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one | 352359-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-chloro-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
• 英文别名: 2-Chloro-8-methylpyrido[2,3-d]pyrimidin-7(8h)-one；2-chloro-8-methylpyrido[2,3-d]pyrimidin-7-one
• CAS: 352359-93-4
• 化学式: C₈H₆ClN₃O
• 分子量: 195.608
• InChiKey: NOBHTIZWMABGSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
  申请人：——

  公开号：US20040224958A1

  公开（公告）日：2004-11-11

  This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula (I) and Formula (II) where W is NH, S, SO, or SO 2 , R 1 includes phenyl and substituted phenyl, R 2 includes alkyl and cycloalkyl, R 3 includes alkyl and hydrogen, R 8 and R 9 include hydrogen and alkyl, and Z is carboxy. This invention also provide pharmaceutical formulations comprising a compound of Formula (I or II) together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. 1

  这项发明提供了对治疗细胞增殖性疾病（如癌症和再狭窄）有用的吡啶吡嘧啶和4-氨基吡嘧啶。我们现在发现了一组7,8-二氢-2（氨基和硫）吡啶嘧啶和2,4-二氨基吡嘧啶，它们是细胞周期依赖性激酶（cdk）和生长因子介导的激酶的有效抑制剂。这些化合物易于合成，并且可以通过多种途径（包括口服）给药，具有足够的生物利用度。该发明提供了式（I）和式（II）的化合物，其中W为NH、S、SO或SO2，R1包括苯基和取代苯基，R2包括烷基和环烷基，R3包括烷基和氢，R8和R9包括氢和烷基，Z为羧基。该发明还提供了含有式（I或II）化合物的制剂，与其一起使用的药用可接受载体、稀释剂或赋形剂。
• 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER
  申请人：Campbell David

  公开号：US20140163026A1

  公开（公告）日：2014-06-12

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

  本文提供了PAK抑制剂及其在治疗中枢神经系统疾病（如神经精神疾病或神经纤维瘤）方面的应用方法。本文还描述了利用PAK抑制剂治疗癌症的方法。
• PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1255755A1

  公开（公告）日：2002-11-13
• [EN] PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE<br/>[FR] DERIVES DE PYRIDOPYRIMIDINONE DESTINES AU TRAITEMENT DE MALADIES MALADIE NEURODEGENERATIVE
  申请人：WARNER LAMBERT CO

  公开号：WO2001055148A1

  公开（公告）日：2001-08-02

  This invention provides a method for treating neurodegenerative diseases in mammals comprising administering an effective amount of a cyclin-dependent kinase inhibitor. A preferred method uses cdk inhibitors of Formula (I) and Formula (II) where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R?8 and R9¿ include hydrogen and alkyl, and Z is carboxy.